Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(1 year, 15 days ago) | |
US7030106
(Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(6 months ago) | |
US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 years from now) | |
US7612058
(Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(3 years from now) |
Market Authorisation Date: 25 October, 2002
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of elevated plasma sterol and/or stanol levels in a mammal
Dosage: TABLET;ORAL
37
United States
17
European Union
12
Japan
9
Australia
9
Canada
8
Austria
8
Hong Kong
8
Spain
8
Germany
8
Slovenia
8
Argentina
8
Portugal
8
China
8
Denmark
7
Mexico
6
Korea, Republic of
6
Cyprus
6
Hungary
6
Norway
6
Ecuador
5
Brazil
5
Slovakia
5
South Africa
5
Russia
5
Czech Republic
5
New Zealand
4
Poland
4
Taiwan, Province of China
2
Israel
1
Morocco
1
RS
1
Chile
1
Malaysia
1
Yugoslavia
1
Georgia
1
Peru
1
ME
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic